A Trial of the Effect of Rosiglitazone as Add on to Metformin Therapy on Endothelial Function in Subjects With Type II DM

Trial Profile

A Trial of the Effect of Rosiglitazone as Add on to Metformin Therapy on Endothelial Function in Subjects With Type II DM

Discontinued
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2010

At a glance

  • Drugs Rosiglitazone (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms GATE
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Mar 2010 Secondary endpoint 'Endothelial function' has not been met according to results presented at the 59th Annual Scientific Session of the American College of Cardiology (ACC 2010).
    • 14 Mar 2010 Results presented at the 59th Annual Scientific Session of the American College of Cardiology (ACC 2010).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top